+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

MaxCyte Inc (MXCT) - Financial and Strategic SWOT Analysis Review

  • ID: 4278923
  • SWOT Analysis
  • July 2021
  • 50 pages
  • GlobalData

FEATURED COMPANIES

  • Apollo Endosurgery Inc
  • DURECT Corp
  • Magenta Therapeutics Inc
  • Vaso Corp
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

MaxCyte Inc (MXCT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

MaxCyte Inc (MaxCyte) discovers, manufactures and commercializes cell-based medicines. The company’s products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx, and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin targeted therapy for treating ovarian and peritoneal mesothelioma; and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for the evolution of chimeric antigen receptor (CAR) immune cell therapies based on non-viral, human messenger RNA (mRNA), and its ExPERT platform facilitates complex cellular engineering to enable the next generation of cellular therapies, which allow molecules to be gently, consistently, and repeatably inserted into cells for specific purposes. Its products are used for designing functional cell-based assays, protein and antibody expression, stable cell line development, viral vector production, gene editing and cell and gene therapies. MaxCyte is headquartered in Gaithersburg, Maryland, the US.

MaxCyte Inc Key Recent Developments

Jul 12,2021: Financial information in the Form S-1 registration statement and Change to Board of Directors
Jul 12,2021: MAXCYTE: S-1 financial information & Directorate change
Jun 16,2021: MaxCyte announce Publication of Annual Report and Accounts
Jun 15,2021: MaxCyte Adds Two New Non-Executive Directors to Its Board
Jun 15,2021: MaxCyte Appoints Two New Non-Executive Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Apollo Endosurgery Inc
  • DURECT Corp
  • Magenta Therapeutics Inc
  • Vaso Corp
  • MORE
List of Figures

Section 1 - About the Company
  • MaxCyte Inc - Key Facts
  • MaxCyte Inc - Key Employees
  • MaxCyte Inc - Key Employee Biographies
  • MaxCyte Inc - Major Products and Services
  • MaxCyte Inc - History
  • MaxCyte Inc - Company Statement
  • MaxCyte Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 – Company Analysis
  • Company Overview
  • MaxCyte Inc - Business Description
  • R&D Overview
  • MaxCyte Inc - Corporate Strategy
  • MaxCyte Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • MaxCyte Inc - Strengths
  • MaxCyte Inc - Weaknesses
  • MaxCyte Inc - Opportunities
  • MaxCyte Inc - Threats
  • MaxCyte Inc - Key Competitors
Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • MaxCyte Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
  • Jul 12, 2021: Financial information in the Form S-1 registration statement and Change to Board of Directors
  • Jul 12, 2021: MAXCYTE: S-1 financial information & Directorate change
  • Jun 16, 2021: MaxCyte announce Publication of Annual Report and Accounts
  • Jun 15, 2021: MaxCyte Adds Two New Non-Executive Directors to Its Board
  • Jun 15, 2021: MaxCyte Appoints Two New Non-Executive Directors
  • Apr 20, 2021: MaxCyte reports final results for the year ended 31 December 2020
  • Feb 23, 2021: MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
  • Dec 23, 2020: MaxCyte: Trading update
  • Oct 13, 2020: MaxCyte Bolsters leadership team with promotion of Brad Calvin to Chief Commercial Officer and new key VP appointments
  • Sep 21, 2020: MaxCyte : Results for the Six Months ended 30 June 2020
Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About Us
  • Contact Us
  • Disclaimer
List of Tables
  • MaxCyte Inc, Key Facts
  • MaxCyte Inc, Key Employees
  • MaxCyte Inc, Key Employee Biographies
  • MaxCyte Inc, Major Products and Services
  • MaxCyte Inc, History
  • MaxCyte Inc, Other Locations
  • MaxCyte Inc, Subsidiaries
  • MaxCyte Inc, Key Competitors
  • MaxCyte Inc, Ratios based on current share price
  • MaxCyte Inc, Annual Ratios
  • MaxCyte Inc, Annual Ratios (Cont...1)
  • MaxCyte Inc, Interim Ratios
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • MaxCyte Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • MaxCyte Inc, Performance Chart (2016 - 2020)
  • MaxCyte Inc, Ratio Charts
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • MaxCyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Vaso Corp
  • Magenta Therapeutics Inc
  • DURECT Corp
  • Apollo Endosurgery Inc
  • Accelerate Diagnostics Inc
Note: Product cover images may vary from those shown
Adroll
adroll